Hepatic Fibrosis and Cirrhosis

Zakim and Boyer's Hepatology

Volumn , Issue , 2006, Pages 87-109

  Rockey, Don C ^a,b   Friedman, Scott L ^c  

^a Division of Digestive and Liver Diseases   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54549110761     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3258-8.50011-5     Document Type: Chapter

References (232)

1. Kim WR, Brown RS, Terrault NA, El-Serag H Burden of liver disease in the United States: summary of a workshop. Hepatology 2002, 36:227-242.
2. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002, 7:D793-D807.
3. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci 2002, 7:D1720-D1726.
4. Friedman SL Liver fibrosis - from bench to bedside. J Hepatol 2003, 38(Suppl 1):S38-S53.
5. Rockey DC Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005, 3:95-107.
6. Bataller R, Brenner DA Liver fibrosis. J Clin Invest 2005, 115:209-218.
7. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 112:463-472.
8. El-Serag HB Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36(Suppl 1):S74-S83.
9. Bruix J, Boix L, Sala M, Llovet JM Focus on hepatocellular cancer. Cancer Cell 2004, 5:215-219.
10. Schuppan D, Ruehl M, Somasundaram R, Hahn EG Matrix as modulator of stellate cell and hepatic fibrogenesis. Semin Liver Dis 2001, 21:351-372.
11. Jarnagin WR, Rockey DC, Koteliansky VE, et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994, 127:2037-2048.
12. Bedossa P, Ferlicot S, Paradis V, et al. Dystroglycan expression in hepatic stellate cells: role in liver fibrosis. Lab Invest 2002, 82:1053-1061.
13. Schiano TD, Kim-Schluger L, Gondolesi G, Miller CM Adult living donor liver transplantation: the hepatologist's perspective. Hepatology 2001, 33:3-9.
14. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001, 34:283-287.
15. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004, 126:1740-1749.
16. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001, 7:567-580.
17. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
18. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:730-739.
19. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31:828-833.
20. Huang H, et al. Hepatology 2004, 40:230A.
21. Shi Z, Wakil AE, Rockey DC Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 1997, 94:10663-10668.
22. Hillebrandt S, Goos C, Matern S, Lammert F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 2002, 123:2041-2051.
23. Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004, 39:826-834.
24. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484-490.
25. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
26. de Torres M, Poynard T Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003, 2:5-11.
27. Wright TL Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002, 36(Suppl 1):S185-S194.
28. Arenas JI, Vargas HE Hepatitis C virus antiviral therapy in patients with cirrhosis. Gastroenterol Clin North Am 2004, 33:549-562. ix.
29. Lindh M, Horal P, Dhillon AP, Norkrans G Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepatol 2000, 7:258-267.
30. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000, 15:1356-1361.
31. Kobayashi M, Arase Y, Ikeda K, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol 2002, 37:35-39.
32. Chen CH, Chen PJ, Chu JS, et al. Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. Gastroenterology 1994, 107:1514-1518.
33. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group [see comments]. N Engl J Med 1998, 339:61-68.
34. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800-807.
35. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
36. Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002, 35:635-638.
37. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001, 21:17-26.
38. Brunt EM Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001, 21:3-16.
39. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
40. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-1123.
41. Kweon YO, Goodman ZD, Dienstag JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001, 35:749-755.
42. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
43. Hammel P, Couvelard A, O'Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001, 344:418-423.
44. Dufour JF, DeLellis R, Kaplan MM Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997, 127:981-985.
45. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998, 102:538-549.
46. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517-524.
47. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: Evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795-1808.
48. Issa R, Williams E, Trim N, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001, 48:548-557.
49. Iredale JP Stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001, 21:427-436.
50. Arthur MJ Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000, 279:G245-G249.
51. Schaefer B, Rivas-Estilla AM, Meraz-Cruz N, et al. Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. Am J Pathol 2003, 162:1771-1780.
52. Han YP, Zhou L, Wang J, et al. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 2004, 279:4820-4828.
53. Benyon D, Arthur MJP Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis 2001, 21:373-384.
54. Friedman SL Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247-2250.
55. Friedman SL, Arthur MJD Reversing hepatic fibrosis. Science and Medicine 2002, 8:194-205.
56. Tsukamoto H. Redox regulation of cytokine expression in Kupffer cells. Antioxid Redox Signal 2002, 4:741-748.
57. Vogel W, Gish GD, Alves F, Pawson T The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1997, 1:13-23.
58. Ikeda K, Wang LH, Torres R, et al. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem 2002, 277:19206-19212.
59. Olaso E, Ikeda K, Eng FJ, et al. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest 2001, 108:1369-1378.
60. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001, 21:397-416.
61. Racine-Samson L, Rockey DC, Bissell DM The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem 1997, 272:30911-30917.
62. Gao R, Brigstock DR Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem 2004, 279:8848-8855.
63. Mazzocca A, Carloni V, Sciammetta S, et al. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol 2002, 37:322-330.
64. Geerts A. History heterogeneity developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001, 21:311-335.
65. Cassiman D, Libbrecht L, Desmet V, et al. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 2002, 36:200-209.
66. Corpechot C, Barbu V, Wendum D, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002, 35:1010-1021.
67. Rockey DC Vascular mediators in the injured liver. Hepatology 2003, 37:4-12.
68. Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004, 126:955-963.
69. Magness ST, Bataller R, Yang L, Brenner DA A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004, 40:1151-1159.
70. Kalluri R, Neilson EG Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112:1776-1784.
71. Tuma DJ Role of malondialdehyde-acetaldehyde adducts in liver injury. Free Radic Biol Med 2002, 32:303-308.
72. Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003, 112:1383-1394.
73. Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003, 83:655-663.
74. Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002, 123:1323-1330.
75. Olaso E, Salado C, Egilegor E, et al. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 2003, 37:674-685.
76. Mann DA, Smart DE Transcriptional regulation of hepatic stellate cell activation. Gut 2002, 50:891-896.
77. Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000, 119:466-478.
78. Hellemans K, Verbuyst P, Quartier E, et al. Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology 2004, 39:97-108.
79. Paik YH, Schwabe RF, Bataller R, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003, 37:1043-1055.
80. Rippe RA, Schrum LW, Stefanovic B, et al. NF-kappaB inhibits expression of the alpha1(I) collagen gene. DNA Cell Biol 1999, 18:751-761.
81. Ratziu V, Lalazar A, Wong L, et al. Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. Proc Natl Acad Sci USA 1998, 95:9500-9505.
82. Kalinichenko VV, Bhattacharyya D, Zhou Y, et al. Foxf1 +/-mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury. Hepatology 2003, 37:107-117.
83. Weiskirchen R, Moser M, Weiskirchen S, et al. LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1. Biochem J 2001, 359(Pt 3):485-496.
84. Rockey DC, Fouassier L, Chung JJ, et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998, 27:472-480.
85. Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996, 110:534-548.
86. Marra F, Grandaliano G, Valente AJ, Abboud HE Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 1995, 22:780-787.
87. Rosenbaum J, Blazejewski S, Preaux AM, et al. Fibroblast growth factor 2 and transforming growth factor beta 1 interactions in human liver myofibroblasts. Gastroenterology 1995, 109:1986-1996.
88. Skrtic S, Wallenius V, Ekberg S, et al. Insulin-like growth factors stimulate expression of hepatocyte growth factor but not transforming growth factor beta1 in cultured hepatic stellate cells. Endocrinology 1997, 138:4683-4689.
89. Pinzani M, Abboud HE, Aron DC Secretion of insulin-like growth factor-I and binding proteins by rat liver fat-storing cells: regulatory role of platelet-derived growth factor. Endocrinology 1990, 127:2343-2349.
90. Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver 1998, 18:2-13.
91. Friedman SL Cytokines and fibrogenesis. Semin Liver Dis 1999, 19:129-140.
92. Reinehr RM, Kubitz R, Peters-Regehr T, et al. Activation of rat hepatic stellate cells in culture is associated with increased sensitivity to endothelin 1. Hepatology 1998, 28:1566-1577.
93. Schnabl B, Kweon YO, Frederick JP, et al. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001, 34:89-100.
94. Dooley S, Delvoux B, Lahme B, et al. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000, 31:1094-1106.
95. Liu C, Gaca MD, Swenson ES, et al. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem 2003, 278:11721-11728.
96. Wells RG Fibrogenesis. V. TGF-beta signaling pathways. Am J Physiol Gastrointest Liver Physiol 2000, 279:G845-G850.
97. Wells RG, Kruglov E, Dranoff JA Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett 2004, 559:107-110.
98. Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 2002, 7:d1899-d1914.
99. Ohata M, Yamauchi M, Takeda K, et al. RAR and RXR expression by Kupffer cells. Exp Mol Pathol 2000, 68:13-20.
100. LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003, 299:890-893.
101. Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003, 52:1347-1354.
102. Ankoma-Sey V, Wang Y, Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 2000, 31:141-148.
103. Schwabe RF, Bataller R, Brenner DA Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 2003, 285:G949-G958.
104. Gaca MD, Zhou X, Benyon RC Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol 2002, 36:362-369.
105. Bataller R, Paik YH, Lindquist JN, et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004, 126:529-540.
106. Efsen E, Grappone C, DeFranco RM, et al. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 2002, 37:39-47.
107. Kobayashi S, Seki S, Kawada N, et al. Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. Cell Tissue Res 2003, 311:353-364.
108. Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004, 127:870-882.
109. Gaca MD, Pickering JA, Arthur MJ, Benyon RC Human and rat hepatic stellate cells produce stem cell factor: a possible mechanism for mast cell recruitment in liver fibrosis. J Hepatol 1999, 30:850-858.
110. Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003, 38:859-868.
111. Mazzocca A, Sciammetta SC, Carloni V, et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem 2005, 280:11329-11339.
112. Bonacchi A, Petrai I, Defranco RM, et al. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 2003, 125:1060-1076.
113. Pohlmann S, Zhang J, Baribaud F, et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003, 77:4070-4080.
114. Ikejima K, Takei Y, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002, 122:1399-1410.
115. Leclercq IA, Farrell GC, Schriemer R, Robertson GR Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002, 37:206-213.
116. Saxena NK, Saliba G, Floyd JJ, Anania FA Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem 2003, 89:311-320.
117. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003, 125:1796-1807.
118. Canbay A, Friedman S, Gores GJ Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39:273-278.
119. Taimr P, Higuchi H, Kocova E, et al. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003, 37:87-95.
120. Trim N, Morgan S, Evans M, et al. Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am J Pathol 2000, 156:1235-1243.
121. Lang A, Schoonhoven R, Tuvia S, et al. Nuclear factor kappaB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J Hepatol 2000, 33:49-58.
122. Reif S, Lang A, Lindquist JN, et al. The role of focal adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem 2003, 278:8083-8090.
123. Preaux AM, D'Ortho MP, Bralet MP, et al. Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. Hepatology 2002, 36:615-622.
124. Li L, Tao J, Davaille J, et al. 15-deoxy-delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J Biol Chem 2001, 276:38152-38158.
125. Yoshiji H, Kuriyama S, Yoshii J, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002, 36:850-860.
126. Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001, 121:685-698.
127. Sohara N, Znoyko I, Levy MT, et al. Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate. J Hepatol 2002, 37:214-221.
128. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999, 29:971-975.
129. Wanless IR, Nakashima E, Sherman M Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000, 124:1599-1607.
130. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-816.
131. Chalasani N, Imperiale TF, Ismail A, et al. Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol 1999, 94:3285-3291.
132. Zaman A, Becker T, Lapidus J, Benner K. Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med 2001, 161:2564-2570.
133. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003, 163:218-224.
134. Sheth SG, Flamm SL, Gordon FD, Chopra S AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998, 93:44-48.
135. Giannini E, Testa R. Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple. Hepatology 2003, 38:1312-1313. author reply 3.
136. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986-992.
137. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
138. Poynard T, Aubert A, Bedossa P, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991, 100:1397-1402.
139. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994, 39:2426-2432.
140. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
141. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004, 3:8.
142. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-230.
143. Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005, 3:167-174.
144. Colombo M, Annoni G, Donato MF, et al. Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: its relationship to hepatic fibrosis, activity of the disease and iron overload. Hepatology 1985, 5:475-479.
145. Tsutsumi M, Takase S, Urashima S, et al. Serum markers for hepatic fibrosis in alcoholic liver disease: which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase?. Alcohol Clin Exp Res 1996, 20:1512-1517.
146. Afdhal NH, Nunes D Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004, 99:1160-1174.
147. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004, 41:935-942.
148. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713.
149. Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004, 39:1239-1247.
150. Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005, 51:328-335.
151. Bora R, Ratziu V, Bedossa P, et al. Diagnostic value of biochemical markers, fibrotest-actitest-HCV-fibrosure compared with serum protein profiling by seldi-TOF, for the diagnosis of bridging fibrosis in patients with chronic hepatitis C. Hepatology 2004, 40:517A.
152. Dev A, White I, Symonds W, et al. Serum proteomic analysis in hepatitis C patients with and without fibrosis. J Hepatol 2005, 42(suppl 2):117A.
153. Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nature Med 2004, 10:429-434.
154. Wells RG The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 2005, 39:S158-S161.
155. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54.
156. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
157. Beljaars L, Meijer DK, Poelstra K Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002, 7:e214-e222.
158. Adler M, Verset D, Bouhdid H, et al. Prognostic evaluation of patients with parenchymal cirrhosis. Proposal of a new simple score. J Hepatol 1997, 26:642-649.
159. Giannini EG, Testa R 13C-breath tests and liver fibrosis. Eur Rev Med Pharmacol Sci 2004, 8:51-54.
160. Giannini EG, Fasoli A, Borro P, et al. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol 2005, 3:279-285.
161. Testa R, Caglieris S, Risso D, et al. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. Am J Gastroenterol 1997, 92:2268-2273.
162. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
163. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
164. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003, 39:239-244.
165. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
166. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005, 41:257-264.
167. Wanless IR, Nakashima E, Sherman M Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000, 124:1599-1607.
168. Powell LW, Kerr JF Reversal of 'cirrhosis' in idiopathic haemochromatosis following long-term intensive venesection therapy. Australas Ann Med 1970, 19:54-57.
169. Blumberg RS, Chopra S, Ibrahim R, et al. Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis. Gastroenterology 1988, 95:1399-1402.
170. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-1017.
171. Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326:507-512.
172. Spahr L, Rubbia-Brandt L, Pugin J, et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001, 35:582-589.
173. Thompson K, Maltby J, Fallowfield J, et al. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis [see comments]. Hepatology 1998, 28:1597-1606.
174. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
175. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002, 37:448-455.
176. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003, 38:419-425.
177. Menon KV, Stadheim L, Kamath PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004, 99:255-260.
178. Schaff Z, Lapis K, Szende B, et al. The effect of D-penicillamine on CCl4-induced experimental liver cirrhosis. Exp Pathol 1991, 43:111-120.
179. Bodenheimer HC, Schaffner F, Sternlieb I, et al. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 1985, 5:1139-1142.
180. Dickson ER, Fleming TR, Wiesner RH, et al. Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 1985, 312:1011-1015.
181. Athal GP, Haugk B, Das S, et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?. Aliment Pharmacol Ther 2004, 19:391-399.
182. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95:3150-3156.
183. Kaplan MM, DeLellis RA, Wolfe HJ Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997, 126:682-688.
184. Hendrickse MT, Rigney E, Giaffer MH, et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial [see comments]. Gastroenterology 1999, 117:400-407.
185. Bach N, Bodian C, Bodenheimer H, et al. Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 2003, 98:187-193.
186. Kaplan MM, Cheng S, Price LL, Bonis PA A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 2004, 39:915-923.
187. Aleynik SI, Leo MA, Ma X, et al. Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. J Hepatol 1997, 27:554-561.
188. Lieber CS, Weiss DG, Groszmann R, et al. II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in Alcoholic Liver Disease. Alcohol Clin Exp Res 2003, 27:1765-1772.
189. Boigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997, 26:643-649.
190. Jia JD, Bauer M, Cho JJ, et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 2001, 35:392-398.
191. Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003, 37:336-339.
192. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989, 9:105-113.
193. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial [see comments]. J Hepatol 1998, 28:615-621.
194. Brown KE, Poulos JE, Li L, et al. Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload. Am J Physiol 1997, 272:G116-G123.
195. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997, 113:1069-1073.
196. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001, 15:1667-1672.
197. Mezey E, Potter J, Rennie-Tankersley L, et al. A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology 2003, 38:264A.
198. Stewart S, Prince M, Bassendine M, et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2002, 36(S):16.
199. Anon The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. J Hepatol 1993, 17:227-235.
200. Lu SC, Tsukamoto H, Mato JM Role of abnormal methionine metabolism in alcoholic liver injury. Alcohol 2002, 27:155-162.
201. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999, 30:1081-1089.
202. Rambaldi A, Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease - a Cochrane Hepato-Biliary Group Review. Liver 2001, 21:398-404.
203. Nava-Ocampo AA, Suster S, Muriel P. Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats. Eur J Clin Invest 1997, 27:77-84.
204. Stiehl A. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Ann Med 1994, 26:345-349.
205. Combes B, Carithers RL, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22:759-766.
206. Jacquemin E, Hermans D, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997, 25:519-523.
207. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998, 27:166-174.
208. Goulis J, Leandro G, Burroughs AK Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999, 354:1053-1060.
209. Poupon RE, Bonnand AM, Chretien Y, Poupon R Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 1999, 29:1668-1671.
210. Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999, 29:1007-1012.
211. Poupon RE, Lindor KD, Pares A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003, 39:12-16.
212. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
213. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol 2002, 97:1674-1681.
214. Rockey DC, Maher JJ, Jarnagin WR, et al. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 1992, 16:776-784.
215. Rockey DC, Chung JJ Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Invest Med 1994, 42:660-670.
216. Ziesche R, Hofbauer E, Wittman K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999, 341:1264-1269.
217. Toyonaga T, Hino O, Sugai S, et al. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci USA 1994, 91:614-618.
218. Muir AJ, Sylvestre PB, Rockey DC. Interferon gamma-1b for the treatment of chronic hepatitis C infection J Viral Hepatitis 2006; in press.
219. Rodriguez L, Cerbon-Ambriz J, Munoz ML Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis. Arch Med Res 1998, 29:109-116.
220. Kaplan MM, Alling DW, Zimmerman HJ, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986, 315:1448-1454.
221. Kershenobich D, Vargas F, Garcia-Tsao G, et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988, 318:1709-1713.
222. Morgan TR, Nemchausky B, Schiff ER, et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: results of a prospective, randomized, placebo-controlled trial. Gastroenterology 2002, 122:641A.
223. Rambaldi A, Gluud C. Colchicine for alcoholic and nonalcoholic liver fibrosis or cirrhosis. Liver 2001, 21:129-136.
224. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996, 2:418-423.
225. George J, Roulot D, Koteliansky VE, Bissell DM In vivo inhibition of rat stellate cell activation by soluble TGF beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999, 96:12719-12724.
226. Yata Y, Gotwals P, Koteliansky V, Rockey DC Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 2002, 35:1022-1030.
227. Pinzani M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996, 148:785-800.
228. Ikeda K, Wakahara T, Wang YQ, et al. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999, 29:1760-1767.
229. Kinnman N, Francoz C, Barbu V, et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 2003, 83:163-173.
230. Di Sario A, Bendia E, Svegliati Baroni G, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 2002, 37:584-591.
231. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000, 275:35715-35722.
232. Bruck R, Genina O, Aeed H, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001, 33:379-386.